"So where does RVX-297 go from here?"

Great question. This question is not limited to RVX-297 but also extends to other compounds as well. Recall that almost a year ago at the October 2016 R&D Day, we were told by Resverlogix that seven compounds had been chosen for follow-on testing. I don't know if RVX-297 is one of these. However, we were told RVX-206, RVX-641, RVX-2101, RVX-2113 were 4 of DM's favorites. We were also told in late 2016 that a 2nd compound has already been chosen as an IND-candidate, but as far as I know: 1) an IND still has not been filed; 2) we don't know what compound this is; and 3) we don't know what indication(s) this is for. There is no mention of RVX-297 or an autoimmune program on the current Resverlogix or Zenith website. Hopefully we get clarity on these issues in the next couple of months.

BearDownAZ